Literature DB >> 8845479

Characterization and mutual ligand-induced modulation of epidermal growth factor and interferon-alpha receptors on renal carcinoma cells in vitro.

H Heise1, H Depenbrock, J W Rastetter, A R Hanauske.   

Abstract

We have determined the binding of epidermal growth factor (EGF) and interferon (IFN)-alpha to their specific receptors on four renal carcinoma cell lines. CaKi-2, a-498 and ACHN cell lines express high numbers, and CaKi-1 expresses low number of EGF receptors (EGFRs). On all four renal carcinoma cell lines, we have also detected specific IFN-alpha binding sites. EGF and IFN-alpha binding to their receptors caused modulation of the other ligand's receptor binding. Scatchard analyses of binding data showed that IFN-alpha treatment leads to an increase of EGFR number in three out of four cell lines and to a decrease of EGFR number in one out of four (CaKi-1). No significant changes in EGF binding affinities were detected. EGF induced a reduction in IFN-alpha receptor number in all four cell lines without significant changes in IFN-alpha binding affinities. We hypothesize that presence of EGF in the microenvironment of renal cancer cells may modulate the biological effects of IFN and consequently decrease its antiproliferative activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8845479     DOI: 10.1097/00001813-199510000-00008

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  2 in total

1.  A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma.

Authors:  Derek Shek; Jeff Longmate; David I Quinn; Kim A Margolin; Przemyslaw Twardowski; David R Gandara; Paul Frankel; Chong-Xian Pan; Primo N Lara
Journal:  Int J Clin Oncol       Date:  2011-03-23       Impact factor: 3.402

2.  Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon alpha.

Authors:  J-L Yang; X-J Qu; P J Russell; D Goldstein
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.